Community types of the human gut virome are associated with endoscopic outcome in ulcerative colitis - Jansen, Daan; Falony, Gwen; Vieira-Silva, Sara; Simsek, Ceren; Marcelis, Tine; Caenepeel, Clara; Machiels, Kathleen; Raes, Jeroen; Vermeire, Séverine; Matthijnssens, Jelle (medRxiv, 2022)
Objective IBD patients have an altered gut virome composition; however, the relationship to disease is unknown. Our aim is to investigate the existence of viral community types and assess the impact of therapeutic outcome (and other covariates) on the gut virome.Design Viral particle enrichment followed by deep sequencing (1.52 TB) was performed on 432 faecal samples from 181 IBD patients (CD=126;UC=55) starting biological therapy. Redundancy analysis and Dirichlet Multinomial Mixtures determined covariates of the virome composition and condensed the gut virota into viral community types.Results IBD patients were stratified based on unsupervised machine learning into two viral community types. Community type CA showed a low α-diversity and a high relative abundance of Caudoviricetes [non-CrAss] phages and was associated to the dysbiotic Bact2-enterotype. Community type CrM showed a high α-diversity and a high relative abundance of Caudoviricetes [CrAss] and Malgrandaviricetes phages. Gut virome variation was explained by patients’ individuality (75.8%), disease location (1.4%), age (0.5%) and faecal moisture (0.3%), with diagnosis not showing a non-redundant effect. Endoscopic outcome (0.5%) was accompanied by gut virome shifts in UC. Non-remitting UC, but not CD, patients revealed a high percentage of community type CA, a low diversity, and a high lysogenic potential. During pre-interventional analysis, we discovered five novel phages with a predictive value for therapeutic outcome.Conclusion The gut virota shows the existence of distinct virome configurations that are associated with endoscopic outcome, and community typing could be a valuable tool to improve our understanding about IBD subtypes, pathology, and activity.Significance of this study What is already known on this subject?Bacterial community typing (‘enterotyping’) is an established practice to stratify individuals based on their bacteriome compositionIBD pathology is repeatedly associated with alterations in the gut virome reflected by a high Caudovirales and low Microviridae abundanceIBD pathology is associated with a shift in phage lifestyle towards a highly lysogenic state of the gut viromeWhat are the new findings?Viral community types exist and could stratify individuals based on their gut virome composition in a large prospective multi-therapeutic IBD cohortViral community types could be associated to the dysbiotic Bact2-enterotypeEndoscopic outcome (remission/non-remission) was a significant covariate of the gut virome composition post-intervention and could be associated with viral community types in UC patientsNon-remitting UC patients revealed a low diversity and a high abundance of lysogenic phagesWe discovered five novel phages (e.g., novel CrAss-like phage) associated with predicting treatment successHow might it impact the clinical practice in the foreseeable future?Viral community types could be a valuable tool to investigate IBD pathology and to differentiate between IBD subtypes and disease activityViral community typing might distinguish a healthy gut from a dysbiotic gut viromeClinical studies should validate phages as predictive biomarkers in IBD patients starting therapyCompeting Interest StatementSeverine Vermeire has received grants from AbbVie, J&J, Pfizer, Galapagos, Takeda. SV has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. Other authors report no conflict of interest.Funding StatementThis research was supported by the Fonds Wetenschappelijk Onderzoek (Research foundation Flanders) (Daan Jansen: 1S78021N, Kathleen Machiels: 12M9118N)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical commission of UZ Leuven (KU Leuven, reference number: S53684). Participants provided signed informed consent to participate with the study. The design of the study was in accordance with the Declaration of Helsinki and Belgian privacy law.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript